Azithromycin in Structural Heart Disease: A Case-Based Approach to Short-Course Arrhythmic Risk

When should I avoid azithromycin in a patient with heart disease and a respiratory infection?

Avoid azithromycin if the patient has meaningful arrhythmia risk or unstable cardiac disease; choose a non–QT-prolonging alternative when possible. In a respiratory infection, the key question is not “heart disease” alone, but whether they have factors that increase risk of QT prolongation, torsades de pointes, or sudd

Which ECG and electrolyte findings most increase torsades risk before a QT-prolonging antibiotic?

Before starting a QT-prolonging antibiotic (for example, a macrolide or fluoroquinolone), the highest-risk pre-treatment findings are a markedly prolonged QTc, recent QTc increase from baseline, bradycardia/pause-dependent rhythms, and uncorrected hypokalaemia or hypomagnesaemia. A QTc ≥500 ms or a rise ≥60 ms from bas

How should cumulative torsades risk be assessed in HF patients taking amiodarone or other QT-active drugs?

In heart failure (HF) patients on amiodarone or other QT-active drugs, assess torsades de pointes (TdP) risk as cumulative rather than drug-specific: combine baseline substrate, current QTc, electrolytes/renal function, bradycardia, and the total QT-drug burden. HF itself is a recognized TdP risk factor, and risk rises

Is a QTc of 470–499 ms enough to avoid azithromycin, or should the total risk profile decide?

A QTc of 470–499 ms is not, by itself, an absolute “never use azithromycin” threshold. In most guidance, the key decision point is the total torsades risk profile, with QTc ≥500 ms or a rise 60 ms from baseline carrying substantially higher concern. - QTc 470–499 ms = already prolonged / borderline-high risk, so azithr

Which non-macrolide options provide adequate respiratory coverage with less arrhythmic risk in structural heart disease?

For respiratory infections where a macrolide would otherwise be considered, the usual non-macrolide option with the lowest arrhythmic concern is doxycycline, because it provides atypical respiratory coverage and is not generally associated with clinically important QT prolongation. In contrast, azithromycin/clarithromy